全球制藥業(yè):蕭條市場(chǎng)入門

全球制藥業(yè):蕭條市場(chǎng)入門

ID:35808287

大小:2.59 MB

頁(yè)數(shù):26頁(yè)

時(shí)間:2019-04-19

全球制藥業(yè):蕭條市場(chǎng)入門_第1頁(yè)
全球制藥業(yè):蕭條市場(chǎng)入門_第2頁(yè)
全球制藥業(yè):蕭條市場(chǎng)入門_第3頁(yè)
全球制藥業(yè):蕭條市場(chǎng)入門_第4頁(yè)
全球制藥業(yè):蕭條市場(chǎng)入門_第5頁(yè)
資源描述:

《全球制藥業(yè):蕭條市場(chǎng)入門》由會(huì)員上傳分享,免費(fèi)在線閱讀,更多相關(guān)內(nèi)容在行業(yè)資料-天天文庫(kù)。

1、GlobalPharmaceuticalsPrimerontheDepressionMarket§DepressionStillaLargeMarket,withPotentialtoReturntoGrowth:DepressionremainsatherapeuticareaofsignificantinvestorinterestgiventhelargepatientpopulationApril3,2019RESEARCHANALYSTSVamilDivan,MD(212)538-5394vamil.divan@credit-suisse.comUyEa

2、r(212)325-1729uy.ear@credit-suisse.comInancCaner(212)325-5051inanc.caner@credit-suisse.comMichaelV.Morabito,Ph.D.(212)-325-7298michael.morabito@credit-suisse.comEuropeanPharmaTeam(44)-207-888-0304creditsuisse.pharmateam@credit-suisse.com(~16.5MMadultsandgrowingintheUSalone)andtheimpa

3、ctthemarketcanhaveonmultiplebiopharmacompanies,withsalesof$4Bnin2018(comingmostlyfromgenericproducts)andgrowingto$6Bnby2026basedonourestimates.Wearepublishingaprimeronthedepressionspacewithalookatcurrentmarkettrendsandthelatestnoveldrugsthatlooktodisruptthemarket.Wewillalsodiscussthis

4、variousdynamicsinthismarketduringoneofourexpertpanelsatour11thAnnualTherapeuticsDaythisFriday,April5.Pleaseletusknowifyouneedmoreinformationonthisevent.§NovelMechanismsLookingtoRejuvenateGenericizedMarket:GenericversionsofolderdrugswithsimilarMOAs(e.g.,SSRIs,SNRIs,NDRIs)currentlyaccou

5、ntfor80%ofprescriptionsintheanti-depressionmarket.Deliveringpositiveclinicaldataindepressiontrialsremainnotoriouslychallenginggivenunpredictableplaceboresponseratesseeninthesetrials.However,weareseeingarenewedinterestbybiopharmacompaniestodevelopnovelanti-depressantswithdifferentmecha

6、nismstoaddresswhatremainsanareaofsignificantunmetmedicalneedandwherethereisapotentiallylargemarketopportunity.§Spravato,ZulressoNewEntrantsIntoAnti-DepressantMarket:BothJNJ’sSpravato(esketamine)fortreatment-resistantdepressionandSAGE’sZulresso(brexanolone)forpost-partumdepressionareno

7、wFDA-approvedandhighlighttheinnovationwecontinuetoseeinthedepressionmarket.However,commercializationandreimbursementdynamicswillbeimportanttowatchforbothproductsgiventhattheirindicationsareforspecificsub-segmentsofthebroaderdepressionpopulationanduniquefeaturesaroundhowthesedrugswillb

8、eadmi

當(dāng)前文檔最多預(yù)覽五頁(yè),下載文檔查看全文

此文檔下載收益歸作者所有

當(dāng)前文檔最多預(yù)覽五頁(yè),下載文檔查看全文
溫馨提示:
1. 部分包含數(shù)學(xué)公式或PPT動(dòng)畫的文件,查看預(yù)覽時(shí)可能會(huì)顯示錯(cuò)亂或異常,文件下載后無此問題,請(qǐng)放心下載。
2. 本文檔由用戶上傳,版權(quán)歸屬用戶,天天文庫(kù)負(fù)責(zé)整理代發(fā)布。如果您對(duì)本文檔版權(quán)有爭(zhēng)議請(qǐng)及時(shí)聯(lián)系客服。
3. 下載前請(qǐng)仔細(xì)閱讀文檔內(nèi)容,確認(rèn)文檔內(nèi)容符合您的需求后進(jìn)行下載,若出現(xiàn)內(nèi)容與標(biāo)題不符可向本站投訴處理。
4. 下載文檔時(shí)可能由于網(wǎng)絡(luò)波動(dòng)等原因無法下載或下載錯(cuò)誤,付費(fèi)完成后未能成功下載的用戶請(qǐng)聯(lián)系客服處理。